SLC5A2 and acute kidney injury: SGLT2 inhibitors showed superiority in reducing the risk of AKI (RR 0.81; 95% CI: 0.73–0.90; p for heterogeneity 0.80; I2 = 0%; p < 0.01) (Figure 6).